Leading pharmaceutical companies are pushing back against U.S. President Donald Trump’s proposed global drug tariffs, warning that an abrupt implementation could disrupt medical supply chains, escalate compliance costs, and limit…
In a major advancement for rare disease treatment and regulatory medicine, the U.S. Food and Drug Administration (FDA) has approved the expanded use of Amgen’s Uplizna (inebilizumab) as the first…
In a significant development within the pharmaceutical regulatory landscape, GlaxoSmithKline (GSK) and Pfizer have agreed to end a high-profile legal dispute involving patent infringement claims tied to their respiratory syncytial…
The Federal Government of Nigeria has approved N32.88 billion under the Basic Health Care Provision Fund (BHCPF) to enhance healthcare delivery, particularly at the grassroots level.
The announcement was made by…
The European Medicines Agency (EMA) has initiated a review of GlaxoSmithKline’s (GSK.L) request to expand the use of its asthma drug Nucala (mepolizumab) as an additional treatment for chronic obstructive…
On World Tuberculosis (TB) Day, the World Health Organization (WHO) has issued a dire warning, emphasizing the urgent need for increased investment in TB care. The organization lamented that severe…
Sanofi (SASY.PA) has entered into an agreement to acquire Dren Bio’s immunology unit, securing rights to its autoimmune disease treatment, DR-0201.
As part of the deal, the French pharmaceutical giant will…
Swiss pharmaceutical giant Roche (ROG.S) has secured the rights to Zealand Pharma’s (ZELA.CO) obesity treatment candidate, petrelintide, in a strategic collaboration valued at up to $5.3 billion. This deal marks…
Governments and global health organizations are mobilizing to address critical gaps in combating diseases such as malaria and HIV following the U.S. government's decision to suspend foreign aid funding. These…